KraneShares MSCI One Belt One Road ETF (OBOR)
Assets | $6.28M |
NAV | $25.12 |
Expense Ratio | 0.79% |
PE Ratio | 13.20 |
Shares Out | 250,000 |
Dividend (ttm) | $0.99 |
Dividend Yield | 3.97% |
Ex-Dividend Date | Dec 29, 2021 |
1-Year Return | -18.47% |
Volume | 29 |
Open | 24.95 |
Previous Close | 24.97 |
Day's Range | 24.95 - 24.98 |
52-Week Low | 24.23 |
52-Week High | 32.31 |
Beta | 0.77 |
Holdings | 154 |
Inception Date | Sep 7, 2017 |
About OBOR
The fund will invest at least 80% of its total assets in components of the index, depositary receipts, including ADRs, representing such components and securities underlying depositary receipts in the index. The underlying index is designed to measure the equity market performance of listed companies with high revenue exposure to the Chinese government's One Belt, One Road initiative, as determined by the provider of the underlying index.
Top 10 Holdings
45.07% of assetsName | Symbol | Weight |
---|---|---|
Cash | n/a | 10.18% |
Oversea-Chinese Banking Corp Ltd | O39.SI | 6.30% |
Contemporary Amperex Technology Co Ltd Class A | 300750.SZ | 5.72% |
Kuwait Finance House KSC | n/a | 4.90% |
Ptt PCL | PTT.BK | 4.12% |
Impala Platinum Holdings Ltd | IMP.JO | 3.88% |
ICL Group Ltd | ICL.TA | 2.87% |
China Yangtze Power Co Ltd Class A | 600900.SS | 2.69% |
Elbit Systems Ltd | ESLT.TA | 2.63% |
ZIM Integrated Shipping Services | ZIM | 1.79% |
Dividends
Ex-Dividend | Amount | Pay Date |
---|---|---|
Dec 29, 2021 | $0.99283 | Dec 31, 2021 |
Dec 29, 2020 | $0.54932 | Dec 31, 2020 |
Dec 27, 2019 | $1.04725 | Dec 31, 2019 |
Dec 26, 2018 | $0.00342 | Dec 28, 2018 |
Dec 19, 2017 | $0.02675 | Dec 22, 2017 |
News
The ‘New Silk Road'? Investing in China's Belt and Road Initiative
China's ambitious infrastructure plan can be packaged in ETF form with the KraneShares MSCI One Belt One Road Index ETF (OBOR). “China's Belt and Road Initiative (BRI), sometimes referred to as the New ...
5 Emerging Market ETFs Surging to Start 2021
Emerging market stocks continued their year-end rally to start 2021 buoyed by a wider rollout of COVID-19 vaccines as well as Joe Biden's victory in the U.S. presidential election.